[Nebivolol: the first vasodilatory beta-blocker with a beta3-adrenergic agonist activity].
Several studies suggest that the beta(3)-adrenergic stimulation could be a new therapeutic target for the treatment of cardiovascular diseases. The vascular effects induced by beta(3)-adrenergic stimulation are able to decrease the left ventricular strain allowing to reduce after-load. In addition, the increased coronary blood flow due to vasorelaxation increases the myocardial oxygene delivery. The hypothesis about the beneficial role of beta(3)-adrenoceptors is supported by recent data about a beta-blocker of third generation, nebivolol, currently used in the treatment of heart failure and hypertension. The present review presents the beta(3)-adrenoceptors characteristics as well as its involvement in the cardiovascular effects of nebivolol.
Gauthier
C
C
INSERM, UMR915, l'institut du thorax, Nantes, F-44000 France. chantal.gauthier@univ-nantes.fr
Trochu
J N
JN
D058671:Adrenergic beta-1 Receptor Antagonists / Q000627:therapeutic use*; D058667:Adrenergic beta-3 Receptor Agonists / Q000627:therapeutic use*; D000818:Animals; D001578:Benzopyrans / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D004983:Ethanolamines / Q000627:therapeutic use*; D006801:Humans; D000068577:Nebivolol; D014665:Vasodilator Agents / Q000627:therapeutic use*
D058671:Adrenergic beta-1 Receptor Antagonists; D058667:Adrenergic beta-3 Receptor Agonists; D001578:Benzopyrans; D004983:Ethanolamines; D014665:Vasodilator Agents; D000068577:Nebivolol